Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Allist Pharmaceuticals, Inc.
With
AbbVie
To assess the safety and tolerability and determine the Recommended phase 2 dose (RP2D) of JAB-3312 in combination with PD1 inhibitor or MEK inhibitor in patients with advanced solid tumors.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must have histologically or cytologically confirmed metastatic or locally advanced solid tumor. Some cohorts must meet specific expression or gene mutation where indicated
Sufficient organ function
Participants must have at least 1 measurable lesion as defined by RECIST v1.1
Must be able to provide an archived tumor sample
ECOG performance status score of 0 or 1.
You may not be if
History of cancer that is histologically distinct from the cancers under study
Active or untreated central nervous system (CNS) metastases
History of pneumonitis or interstitial lung disease (ILD)
Has active hepatitis B, hepatitis C infection, HIV
Any severe and/or uncontrolled medical conditions
LVEF ≤50%
QTcF \>470 msec
Clareo Health | JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors
